

# ZERO X 40

## BAYER

Bayer is a global enterprise and one of the world's leading companies in the fields of healthcare and agriculture. Its products and services are designed to benefit people and improve their quality of life.

With over 150 years of expertise in the Life Sciences, the Group is in a unique position to provide both vector control solutions and medicines to prevent and cure vector-borne and neglected tropical diseases. In addition, as one of the world's leading companies in agriculture, Bayer seeks to better understand correlations between smallholder and large scale farming and malaria, a predominantly rural disease and a leading cause of poverty. Using this knowledge Bayer aims to offer sustainable malaria prevention to this high-risk group of people.

Understanding the urgency, magnitude and complexity of malaria and other diseases transmitted by mosquitoes, Bayer takes a holistic and integrated approach to vector control. With more than 60 years' experience in public health, Bayer offers indoor residual sprays, larvicides and supplies active ingredients for use in long-lasting insecticide-treated nets for malaria prevention. These combined interventions remain the most effective and cost-efficient means to prevent the disease today. With 15 product specifications on the former WHO Pesticides Evaluation Scheme list, Bayer has supplied product to protect more than 180 million people against vector-borne diseases such as malaria since 2010.

Committed to address emerging challenges, Bayer is investing significantly in the development of innovative solutions to address insecticide resistance. To this end, the company is pursuing the development of a completely new active ingredient in partnership with the Innovative Vector Control Consortium which, assuming successful progress through development phases, should be available for use in the coming years. However, with solutions to insecticide resistance needed urgently, Bayer has developed Fludora® Fusion, the first indoor residual spray combining two unrelated modes of action, providing optimum effectiveness under conditions of insecticide resistance. Listing with WHO-PQ is expected at the end of 2018, after which the product will be eligible for use by large-scale malaria vector control programs.

Recognizing that the challenge to eradicate vector-borne diseases is far too immense and widespread for one company alone, Bayer collaborates with international organisations, foundations and governments. The most recent partnership was made in 2017 with Goodbye Malaria, a non-profit organisation supporting vector control program implementation in Southern Africa, advocating indoor residual spray as a key tool to combat malaria and educating people about disease elimination.

In the field of education Bayer invests in capacity building, supporting the future generation of entomologists at the London School of Hygiene and Tropical Medicine (LSHTM) with grants to support their studies.

Through science, innovation and collaboration, Bayer strives to help find solutions to eradicate malaria and neglected tropical diseases, helping to create a Better Life for millions of people across the world.

For more information about Bayer, go to [www.bayer.com](http://www.bayer.com)

For information about Bayer's Vector Control business, see <https://www.vectorcontrol.bayer.com/>